Dual hepatic metabolism of cerivastatin--clarifications.
Guyton
J R
JR
Dujovne
C A
CA
Illingworth
D R
DR
D000368:Aged; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D015248:Gemfibrozil / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics*; D006949:Hyperlipidemias / Q000188:drug therapy / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000493:pharmacokinetics; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics*; D012206:Rhabdomyolysis / Q000139:chemically induced / Q000378:metabolism; D013237:Stereoisomerism
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011725:Pyridines; C086276:cerivastatin; D015248:Gemfibrozil